GlassScriptPhysician profile
Sara S Patrawala
NPI 1821373705
$7,656.26
in general payments reported to CMS, 2019-2025
13 companies · $4,655 in 2025
The $4,655 reported for 2025 was more than what 83% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,431 · 2022: $299 · 2023: $782 · 2024: $489 · 2025: $4,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,746 · Food and Beverage: $2,146 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,746.00 |
| Food and Beverage | $2,146.43 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $2,304.47 | 2025 | Joenja |
| Genzyme Corporation | $1,805.89 | 2023-2025 | |
| Glaxosmithkline, LLC. | $1,012.81 | 2021-2025 | Nucala, Arexvy |
| Allerderm Laboratories | $1,000.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $403.36 | 2021-2025 | Tezspire |
| Amgen INC. | $304.70 | 2023-2025 | Tezspire |
| Alk-Abello, INC | $210.08 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $140.33 | 2025 | |
| Genentech USA, INC. | $124.23 | 2024 | Xolair |
| Grifols USA, LLC | $109.23 | 2024 | Xembify |
| Regeneron Healthcare Solutions, INC. | $109.01 | 2022 | |
| Ionis Pharmaceuticals, INC. | $95.00 | 2025 | |
| Ucb, INC. | $37.15 | 2025 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Patrawala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.